Kymera Therapeutics, Inc. (KYMR) just reported positive results from its phase 1 healthy volunteer study using KT-621. The purpose of this clinical candidate is to develop it as an oral STAT6 protein ...
– CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with toripalimab – – Confirmed partial response in heavily pretreated PD-1 refractory patient supports expansion ...
Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025 Positive, early results ...
Monte Rosa Therapeutics, Inc. has initiated a Phase 1 study for MRT-8102, a novel molecular glue degrader targeting the NEK7 protein to treat inflammatory conditions linked to the NLRP3 inflammasome.
Hosted on MSN
Incyte’s Phase 1 Study on INCB160058: A Potential Breakthrough in Blood Cancer Treatment
Incyte ((INCY)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help ...
Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today ...
BioAtla, Inc. has announced promising preliminary results from a Phase 1 clinical trial of BA3182, a dual-Conditionally Active Biologic bispecific T-cell engager targeting EpCAM and CD3, for treating ...
Canadian Cancer Trials Group (CCTG) IND.234/223: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)–A molecularly selected cooperative group platform study. This is an ASCO Meeting ...
ETD001 is well tolerated in healthy individuals at higher doses than predicted to be therapeutic for long-lasting enhancement of mucociliary clearance Results showed excellent consistency between ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results